DURECT Corporation (NASDAQ:DRRX) had its price objective decreased by equities research analysts at Laidlaw from $3.00 to $2.00 in a note issued to investors on Friday. The brokerage presently has a “buy” rating on the specialty pharmaceutical company’s stock. Laidlaw’s price target suggests a potential upside of 1.52% from the stock’s current price.

A number of other research analysts have also commented on the company. Stifel Nicolaus raised DURECT Corporation from a “hold” rating to a “buy” rating and raised their price target for the company from $1.25 to $3.00 in a report on Wednesday, July 12th. HC Wainwright reissued a “buy” rating and set a $3.00 price target on shares of DURECT Corporation in a report on Sunday, June 25th. Finally, ValuEngine raised DURECT Corporation from a “sell” rating to a “hold” rating in a report on Tuesday, September 26th.

DURECT Corporation (NASDAQ:DRRX) opened at 1.97 on Friday. The stock’s market capitalization is $289.59 million. The company has a 50-day moving average of $1.78 and a 200-day moving average of $1.46. DURECT Corporation has a 52-week low of $0.74 and a 52-week high of $2.17.

DURECT Corporation (NASDAQ:DRRX) last issued its quarterly earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.07) EPS for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.02). The business had revenue of $4.32 million for the quarter, compared to analyst estimates of $5.17 million. DURECT Corporation had a negative net margin of 221.01% and a negative return on equity of 629.35%. Equities research analysts expect that DURECT Corporation will post ($0.21) EPS for the current year.

COPYRIGHT VIOLATION WARNING: “DURECT Corporation (DRRX) PT Lowered to $2.00 at Laidlaw” was originally reported by Daily Political and is the sole property of of Daily Political. If you are accessing this piece on another publication, it was copied illegally and republished in violation of U.S. & international trademark & copyright legislation. The original version of this piece can be read at https://www.dailypolitical.com/2017/10/20/durect-corporation-drrx-pt-lowered-to-2-00-at-laidlaw.html.

Institutional investors and hedge funds have recently modified their holdings of the company. Tower Research Capital LLC TRC acquired a new position in shares of DURECT Corporation during the first quarter valued at $118,000. Gagnon Securities LLC increased its holdings in shares of DURECT Corporation by 35.9% during the second quarter. Gagnon Securities LLC now owns 1,283,954 shares of the specialty pharmaceutical company’s stock valued at $2,003,000 after purchasing an additional 338,881 shares during the period. Ironwood Investment Management LLC increased its holdings in shares of DURECT Corporation by 0.6% during the first quarter. Ironwood Investment Management LLC now owns 472,029 shares of the specialty pharmaceutical company’s stock valued at $496,000 after purchasing an additional 2,785 shares during the period. Mangrove Partners acquired a new position in shares of DURECT Corporation during the second quarter valued at $530,000. Finally, SG Americas Securities LLC acquired a new position in shares of DURECT Corporation during the first quarter valued at $147,000. 45.82% of the stock is currently owned by institutional investors.

About DURECT Corporation

Durect Corporation is a biopharmaceutical company with research and development programs. The Company’s products candidates include DUR-928, oral for metabolic/lipid disorders, and DUR-928, injectable for acute organ injuries. Its other product candidates include POSIMIR (controlled release injection of bupivacaine), REMOXY (oral controlled release oxycodone), ORADUR-ADHD, ELADUR (controlled release injection of bupivicane), Relday (risperidone), ORADUR-based opioid (hydromorphone) and SABER-based ophthalmic.

Receive News & Ratings for DURECT Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DURECT Corporation and related companies with MarketBeat.com's FREE daily email newsletter.